XERS
Xeris Biopharma Holdings, Inc.
$6.18
+0.49%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Inst. Holders9 funds
Inst. Value$155.3M
Inst. Activity2 buys / 2 sells
Insider Activity0B / 10S
Insider Net $-$994.5K
SEC Reports5
Recent Activity
Jun 5, 2026
SEC
Two Xeris insiders (Director Persky and officer Hecht) sold a combined $192K in open-market sales over a 3-day window. T
CLUSTER — Impact 3/10
Jun 5, 2026
SEC
A cluster of insider selling at Xeris Biopharma, totaling $192K in open-market sales by two directors and an officer, oc
CLUSTER — Impact 3/10
Jun 5, 2026
SEC
Director Marla Persky filed a Form 144 notice of intent to sell 15,500 shares of XERS common stock, with an estimated ag
144 — Impact 2/10
Jun 4, 2026
Insider
Kong Garheng sold 32,996 shares
Director @ $6.15 ($202.9K)
Jun 4, 2026
Insider
Kong Garheng sold 24,193 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
PERSKY MARLA sold 32,996 shares
Director @ $6.15 ($202.9K)
Inst.
NORGES BANK — NEW
800,700 shares ($6.3M)
Inst.
BANK OF AMERICA CORP — TRIM
717,914 shares ($5.6M)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$11.29 (Mar 2026)
Current $6.18
Low $8.00
Median $10.00
High $18.00
7 analysts
$8.00
$18.00
Analyst Ratings
5Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 9, 2025 | Barclays | INITIATE | Overweight |
| Nov 7, 2025 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Nov 7, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $0.04 ▼ -14.6% | $0.03 — $0.05 | 0% YoY | 4 |
| Next FY | $0.40 ▲ +6.6% | $0.24 — $0.60 | 177% YoY | 4 |
| Current FY | $0.14 | $0.10 — $0.19 | 0% YoY | 4 |
| Current Q | $0.00 ▼ -69.0% | $-0.01 — $0.02 | 133% YoY | 3 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two Xeris insiders (Director Persky and officer Hecht) sold a combined $192K in open-market sales over a 3-day window. T
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider selling at Xeris Biopharma, totaling $192K in open-market sales by two directors and an officer, oc
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $87.8M | — |
| MORGAN STANLEY | $21.3M | ADD |
| TWO SIGMA INVESTMENTS, LP | $13.6M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $11.0M | DOUBLED |
| NORGES BANK | $6.3M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Kong Garheng | A | $202.9K |
| Jun 4, 2026 | Kong Garheng | A | $0.00 |
| Jun 4, 2026 | PERSKY MARLA | A | $202.9K |
| Jun 4, 2026 | PERSKY MARLA | A | $0.00 |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN | A | $202.9K |
9 institutional holders with $155.3M total value (19,779,726 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, TWO.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 11,186,677 | $87.8M | 56.6% | — |
| 2 | MORGAN STANLEY | 2,707,783 | $21.3M | 13.7% | ADD +49.0% |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,732,667 | $13.6M | 8.8% | ADD +32.9% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,403,824 | $11.0M | 7.1% | DOUBLED +154.9% |
| 5 | NORGES BANK | 800,700 | $6.3M | 4.0% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 717,914 | $5.6M | 3.6% | TRIM -55.0% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 619,660 | $4.9M | 3.1% | TRIM -61.8% |
| 8 | FMR LLC | 439,705 | $3.5M | 2.2% | DOUBLED +552.0% |
| 9 | WELLS FARGO & COMPANY/MN | 170,796 | $1.3M | 0.9% | ADD +75.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 800,700 | — | $6.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,594,866 | 717,914 | -55.0% | $5.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,622,840 | 619,660 | -61.8% | $4.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 97,196 | 170,796 | +75.7% | $1.3M | 2025-Q4 |
| UBS Group AG | DOUBLED | 227,865 | 1,782,734 | +682.4% | $14.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 1,214,699 | 1,614,579 | +32.9% | $13.1M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 567,538 | 1,446,619 | +154.9% | $11.8M | 2025-Q3 |
| NORGES BANK | EXIT | 561,700 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 890,337 | 1,214,699 | +36.4% | $5.7M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 423,775 | 567,538 | +33.9% | $2.7M | 2025-Q2 |
| NORGES BANK | NEW | — | 561,700 | — | $2.6M | 2025-Q2 |
| UBS Group AG | TRIM | 863,776 | 227,865 | -73.6% | $1.1M | 2025-Q2 |
| MORGAN STANLEY | ADD | 2,877,516 | 4,288,281 | +49.0% | $23.5M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 868,028 | 1,431,159 | +64.9% | $7.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 890,337 | — | $4.9M | 2025-Q1 |
| UBS Group AG | TRIM | 1,734,491 | 863,776 | -50.2% | $4.7M | 2025-Q1 |
| FMR LLC | DOUBLED | 47,774 | 311,472 | +552.0% | $1.7M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,598,720 | 2,098,840 | +31.3% | $7.1M | 2024-Q4 |
| UBS Group AG | DOUBLED | 283,252 | 1,734,491 | +512.3% | $5.9M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 142,200 | 868,028 | +510.4% | $2.9M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 56,986 | 79,036 | +38.7% | $267.9K | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,609,924 | 2,354,308 | +46.2% | $6.7M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 403,361 | — | $1.1M | 2024-Q3 |
11 unique insiders with 10 transactions. Net insider value: -$994.5K ($0.00 bought, $994.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Kong Garheng | Director | A | 32,996 | $6.15 | $202.9K |
| Jun 4, 2026 | Kong Garheng | Director | A | 24,193 | $0.00 | $0.00 |
| Jun 4, 2026 | PERSKY MARLA | Director | A | 32,996 | $6.15 | $202.9K |
| Jun 4, 2026 | PERSKY MARLA | Director | A | 24,193 | $0.00 | $0.00 |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | A | 32,996 | $6.15 | $202.9K |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | A | 24,193 | $0.00 | $0.00 |
| Jun 4, 2026 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | SELL | 16,000 | $6.09 | $97.5K |
| Jun 4, 2026 | HALKUFF DAWN | Director | A | 32,996 | $6.15 | $202.9K |
| Jun 4, 2026 | HALKUFF DAWN | Director | A | 24,193 | $0.00 | $0.00 |
| Jun 4, 2026 | JOHNSON JOHN | Director | A | 32,996 | $6.15 | $202.9K |
| Jun 4, 2026 | JOHNSON JOHN | Director | A | 24,193 | $0.00 | $0.00 |
| Jun 4, 2026 | HALKUFF DAWN | Director | SELL | 20,000 | $6.09 | $121.9K |
| Jun 4, 2026 | JOHNSON JOHN | Director | SELL | 15,000 | $6.09 | $91.4K |
| Jun 4, 2026 | Brady James Aloysius | Director | A | 32,996 | $6.15 | $202.9K |
| Jun 4, 2026 | Brady James Aloysius | Director | A | 24,193 | $0.00 | $0.00 |
| Jun 3, 2026 | PERSKY MARLA | Director | SELL | 15,500 | $5.90 | $91.4K |
| Jun 1, 2026 | Hecht Beth | See Remarks | SELL | 16,667 | $6.06 | $101.0K |
| May 1, 2026 | Hecht Beth | See Remarks | SELL | 16,667 | $6.23 | $103.8K |
| Apr 1, 2026 | Hecht Beth | See Remarks | SELL | 16,667 | $5.99 | $99.9K |
| Mar 30, 2026 | Brady James Aloysius | Director | SELL | 10,834 | $5.54 | $60.0K |
| Mar 12, 2026 | McCulloch Kevin | See Remarks | M | 48,894 | $4.09 | $200.0K |
| Mar 12, 2026 | McCulloch Kevin | See Remarks | M | 48,894 | $4.09 | $200.0K |
| Mar 5, 2026 | Pieper Steven | See Remarks | M | 27,891 | $0.00 | $0.00 |
| Mar 5, 2026 | Pieper Steven | See Remarks | M | 27,891 | $4.09 | $114.1K |
| Mar 2, 2026 | Hecht Beth | See Remarks | SELL | 16,567 | $6.24 | $103.4K |
| Feb 24, 2026 | Nguyen Anh Tu | See Remarks | F | 29,300 | $6.88 | $201.6K |
| Feb 2, 2026 | Hecht Beth | See Remarks | SELL | 16,667 | $7.45 | $124.1K |
| Jan 31, 2026 | Hecht Beth | See Remarks | F | 98,375 | $7.36 | $724.0K |
| Jan 31, 2026 | Pieper Steven | See Remarks | F | 111,765 | $7.36 | $822.6K |
| Jan 31, 2026 | McCulloch Kevin | See Remarks | F | 68,454 | $7.36 | $503.8K |
| Jan 31, 2026 | Shannon John Patrick Jr | See Remarks | F | 118,134 | $7.36 | $869.5K |
| Jan 30, 2026 | Nguyen Anh Tu | See Remarks | A | 162,162 | $0.00 | $0.00 |
| Jan 30, 2026 | Nguyen Anh Tu | See Remarks | A | 121,293 | $0.00 | $0.00 |
| Jan 30, 2026 | Hecht Beth | See Remarks | A | 162,162 | $0.00 | $0.00 |
| Jan 30, 2026 | Hecht Beth | See Remarks | A | 121,293 | $0.00 | $0.00 |
| Jan 30, 2026 | Pieper Steven | See Remarks | A | 207,207 | $0.00 | $0.00 |
| Jan 30, 2026 | Pieper Steven | See Remarks | A | 154,986 | $0.00 | $0.00 |
| Jan 30, 2026 | McCulloch Kevin | See Remarks | A | 225,225 | $0.00 | $0.00 |
| Jan 30, 2026 | McCulloch Kevin | See Remarks | A | 168,463 | $0.00 | $0.00 |
| Jan 30, 2026 | Shannon John Patrick Jr | See Remarks | A | 639,639 | $0.00 | $0.00 |
| Jan 30, 2026 | Shannon John Patrick Jr | See Remarks | A | 478,436 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 2.6/10.
NEUTRAL
CLUSTER
3/10
Two Xeris insiders (Director Persky and officer Hecht) sold a combined $192K in open-market sales ov
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider selling at Xeris Biopharma, totaling $192K in open-market sales by two director
Jun 5, 2026
NEUTRAL
144
2/10
Director Marla Persky filed a Form 144 notice of intent to sell 15,500 shares of XERS common stock,
Jun 5, 2026
NEUTRAL
144
2/10
Director Dawn Halkuff filed a Form 144 notice of intent to sell 20,000 shares of Xeris Biopharma com
Jun 4, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for Xeris
Feb 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Mar 2026): 85% buy across 13 analysts — 5 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$11.29 mean target (Mar 2026)
$8.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $6.18 |
| Target Low | $8.00 |
| Target Mean | $11.29 |
| Target Median | $10.00 |
| Target High | $18.00 |
| # Analysts | 7 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-09-30 |
$0.04 | $0.03 | $0.05 | 0.0% | -14.6% | 1↑ 1↓ | $0.1B | 36.2% | 4 |
| Next FY 2027-12-31 |
$0.40 | $0.24 | $0.60 | 177.2% | +6.6% | 2↑ 2↓ | $0.5B | 22.7% | 4 |
| Current FY 2026-12-31 |
$0.14 | $0.10 | $0.19 | 0.0% | +0.2% | 2↑ 1↓ | $0.4B | 32.2% | 4 |
| Current Q 2026-06-30 |
$0.00 | $-0.01 | $0.02 | 133.3% | -69.0% | 1↑ 0↓ | $0.1B | 27.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.003 | |
| 7d ago | $0.008 | -0.004 |
| 30d ago | $0.011 | -0.007 |
| 60d ago | $0.007 | -0.003 |
| 90d ago | $0.070 | -0.066 |
9 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 6 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 9, 2025 | Barclays | INITIATE | — | Overweight |
| Nov 7, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Nov 7, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 7, 2025 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| Oct 29, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Sep 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 19, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Aug 8, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Aug 8, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jun 5, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| May 9, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 7, 2025 | Piper Sandler | REITERATE | Neutral | Neutral |
| Mar 7, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Mar 7, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Mar 7, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 29, 2025 | Jefferies | REITERATE | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 11, 2024 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 10, 2024 | Piper Sandler | REITERATE | Overweight | Overweight |
| Mar 28, 2024 | Oppenheimer | INITIATE | — | Outperform |
| Mar 7, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 10, 2023 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Aug 28, 2023 | Craig-Hallum | INITIATE | — | Buy |
| Aug 9, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 10, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 9, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Jan 27, 2023 | SVB Leerink | MAINTAIN | — | Outperform |
| Apr 28, 2022 | Craig-Hallum | INITIATE | — | Buy |
| Mar 16, 2022 | Mizuho | MAINTAIN | — | Buy |
| Feb 16, 2022 | SVB Leerink | MAINTAIN | — | Outperform |
| Dec 31, 2021 | SVB Leerink | MAINTAIN | — | Outperform |
| Dec 31, 2021 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Nov 17, 2021 | SVB Leerink | INITIATE | — | Outperform |
| Oct 29, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
XERS Q1 2026 Earnings Scheduled — 2026-05-07
Mar 2, 2026
earnings_calendar
XERS Q4 2025 Earnings After Market Close — 2026-03-02